JBIC funds Ajinomoto's deal to buy US gene therapy group Forge

In:

Infrastructure

Region:

Asia-Pacific

JBIC has agreed a loan of up to JPY57 billion (just over $362 million) with Ajinomoto to allow the Japanese biotech company to acquire US-based Forge Biologics Holdings. The co-financing amount is JPY97 billion.Through the deal, Ajinomoto aims to combine Forge's gene therapy CDMO platform with...

Exclusive subscriber content…

If you are a TXF subscriber, please login to continue reading

Not yet a subscriber? Join us today to continue accessing content without any restrictions

View our subscription options

Or to request access to TXF Intelligence contact us

Request Access

Perspective

02 September 2024

Too high a price

Africa pays a premium for its debt that in many instances it should not. Why the onerous debt costs? And what can be done about it without major systemic change?

Perspective

06 September 2024

If I had a nickel

ECAs, DFIs and banks to Madagascar’s Ambatovy nickel mine project financing are facing a wipe out of $1.66 billion loans under a new shareholder restructuring proposal. Though...

Must See

TXF export finance H1 data pt 2: New tech drives European deal flow

Perspective

02 September 2024

TXF export finance H1 data pt 2: New tech drives European deal flow

New asset classes are emerging as ECAs get smarter in how they extend to support, from EV gigafactories to mining deals. And developing markets are slowly becoming higher on the financing agenda.

Perspective

02 September 2024

Too high a price

Africa pays a premium for its debt that in many instances it should not. Why the onerous debt costs? And what can be done about it without major systemic change?

Perspective

06 September 2024

If I had a nickel

ECAs, DFIs and banks to Madagascar’s Ambatovy nickel mine project financing are facing a wipe out of $1.66 billion loans under a new shareholder restructuring proposal. Though some of the owed debt could be recovered – if lenders stump up new cash.